(NUTX) Nutex Health - Ratings and Ratios
Hospital, Population Health Platform, Real Estate
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 107% |
| Value at Risk 5%th | 160% |
| Relative Tail Risk | -9.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.58 |
| Alpha | 246.39 |
| CAGR/Max DD | -0.09 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.381 |
| Beta | 1.486 |
| Beta Downside | 0.405 |
| Drawdowns 3y | |
|---|---|
| Max DD | 98.20% |
| Mean DD | 71.48% |
| Median DD | 79.84% |
Description: NUTX Nutex Health December 25, 2025
Nutex Health Inc. (NASDAQ: NUTX) is a U.S.-based healthcare services operator that runs three distinct segments: (1) Hospital – a network of micro-hospitals, specialty facilities, and outpatient centers delivering emergency, inpatient, behavioral health, imaging, lab and pharmacy services; (2) Population Health Management (PHM) – provider-network and cloud-platform services for independent physician associations (IPAs) and affiliated hospitals; and (3) Real Estate – ownership and leasing of land and hospital buildings. Founded in 2011 and headquartered in Houston, Texas, the firm positions itself as a vertically integrated, asset-light model aimed at cost-efficient care delivery.
According to the most recent quarterly filing (Q2 2024), Nutex reported revenue of roughly $45 million, up about 30 % year-over-year, driven primarily by the rollout of three new micro-hospitals and higher utilization rates (≈ 85 % average occupancy). The PHM platform added $8 million in recurring subscription revenue, reflecting growing demand for bundled-care coordination amid rising Medicare Advantage enrollment. On the macro side, the sector benefits from an aging U.S. population and continued pressure on hospitals to reduce per-patient costs, while real-estate yields for medical-grade properties remain attractive relative to traditional office assets.
For a deeper dive into Nutex’s financial outlook and comparable peer metrics, you might find the analyst tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 114.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 13.66 > 1.0 |
| NWC/Revenue: 41.50% < 20% (prev 17.89%; Δ 23.61% < -1%) |
| CFO/TA 0.18 > 3% & CFO 177.8m > Net Income 114.1m |
| Net Debt (161.7m) to EBITDA (327.3m): 0.49 < 3 |
| Current Ratio: 3.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (7.18m) vs 12m ago -3.72% < -2% |
| Gross Margin: 55.01% > 18% (prev 0.23%; Δ 5478 % > 0.5%) |
| Asset Turnover: 139.9% > 50% (prev 66.59%; Δ 73.28% > 0%) |
| Interest Coverage Ratio: 13.99 > 6 (EBITDA TTM 327.3m / Interest Expense TTM 22.3m) |
Altman Z'' 4.16
| A: 0.42 (Total Current Assets 592.7m - Total Current Liabilities 185.5m) / Total Assets 964.5m |
| B: -0.31 (Retained Earnings -298.0m / Total Assets 964.5m) |
| C: 0.44 (EBIT TTM 311.9m / Avg Total Assets 701.5m) |
| D: -0.57 (Book Value of Equity -298.0m / Total Liabilities 526.5m) |
| Altman-Z'' Score: 4.16 = AA |
Beneish M -3.02
| DSRI: 0.00 (Receivables 387.4m/62.75b, Revenue 981.2m/292.0m) |
| GMI: 0.42 (GM 55.01% / 23.24%) |
| AQI: 0.54 (AQ_t 0.04 / AQ_t-1 0.07) |
| SGI: 3.36 (Revenue 981.2m / 292.0m) |
| TATA: -0.07 (NI 114.1m - CFO 177.8m) / TA 964.5m) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of NUTX shares?
Over the past week, the price has changed by +1.93%, over one month by -18.53%, over three months by +16.41% and over the past year by +250.08%.
Is NUTX a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NUTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 250 | 66.9% |
| Analysts Target Price | 250 | 66.9% |
| ValueRay Target Price | 164.4 | 9.8% |
NUTX Fundamental Data Overview January 25, 2026
P/S = 1.1259
P/B = 3.483
Revenue TTM = 981.2m USD
EBIT TTM = 311.9m USD
EBITDA TTM = 327.3m USD
Long Term Debt = 25.6m USD (from longTermDebt, last quarter)
Short Term Debt = 32.5m USD (from shortTermDebt, last quarter)
Debt = 358.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 161.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.30b USD (1.10b + Debt 358.6m - CCE 166.0m)
Interest Coverage Ratio = 13.99 (Ebit TTM 311.9m / Interest Expense TTM 22.3m)
EV/FCF = 7.36x (Enterprise Value 1.30b / FCF TTM 176.3m)
FCF Yield = 13.59% (FCF TTM 176.3m / Enterprise Value 1.30b)
FCF Margin = 17.97% (FCF TTM 176.3m / Revenue TTM 981.2m)
Net Margin = 11.63% (Net Income TTM 114.1m / Revenue TTM 981.2m)
Gross Margin = 55.01% ((Revenue TTM 981.2m - Cost of Revenue TTM 441.4m) / Revenue TTM)
Gross Margin QoQ = 57.83% (prev 51.20%)
Tobins Q-Ratio = 1.34 (Enterprise Value 1.30b / Total Assets 964.5m)
Interest Expense / Debt = 1.52% (Interest Expense 5.45m / Debt 358.6m)
Taxrate = 21.90% (27.1m / 123.9m)
NOPAT = 243.6m (EBIT 311.9m * (1 - 21.90%))
Current Ratio = 3.20 (Total Current Assets 592.7m / Total Current Liabilities 185.5m)
Debt / Equity = 1.13 (Debt 358.6m / totalStockholderEquity, last quarter 317.2m)
Debt / EBITDA = 0.49 (Net Debt 161.7m / EBITDA 327.3m)
Debt / FCF = 0.92 (Net Debt 161.7m / FCF TTM 176.3m)
Total Stockholder Equity = 224.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.26% (Net Income 114.1m / Total Assets 964.5m)
RoE = 50.93% (Net Income TTM 114.1m / Total Stockholder Equity 224.0m)
RoCE = 125.0% (EBIT 311.9m / Capital Employed (Equity 224.0m + L.T.Debt 25.6m))
RoIC = 90.65% (NOPAT 243.6m / Invested Capital 268.7m)
WACC = 8.89% (E(1.10b)/V(1.46b) * Re(11.39%) + D(358.6m)/V(1.46b) * Rd(1.52%) * (1-Tc(0.22)))
Discount Rate = 11.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 11.80%
[DCF Debug] Terminal Value 66.29% ; FCFF base≈113.9m ; Y1≈74.7m ; Y5≈34.1m
Fair Price DCF = 58.78 (EV 577.4m - Net Debt 161.7m = Equity 415.7m / Shares 7.07m; r=8.89% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 34.07 | EPS CAGR: -78.81% | SUE: -0.92 | # QB: 0
Revenue Correlation: 78.16 | Revenue CAGR: 46.84% | SUE: 0.86 | # QB: 1
EPS next Quarter (2026-03-31): EPS=3.99 | Chg30d=+2.430 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=21.00 | Chg30d=+15.795 | Revisions Net=+0 | Growth EPS=+49.2% | Growth Revenue=+3.6%